Moderna (MRNA) Inventory (2020 - 2026)

Moderna (MRNA) has 7 years of Inventory data on file, last reported at $146.0 million in Q1 2026.

• Inventory for Q1 2026 came in at $146.0 million, up 14.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $146.0 million (up 14.06% YoY), and the FY2025 annual result was $153.0 million, up 30.77% from the prior year.
• Inventory slipped to $146.0 million in Q1 2026 per MRNA's latest filing, from $153.0 million in the prior quarter.
• Over five years, Inventory peaked at $2.1 billion in Q3 2022 and troughed at $117.0 million in Q4 2024.
• A 5-year average of $661.6 million and a median of $399.0 million in 2024 frame the typical range for Inventory.
• The sharpest annual moves came in 2022 and 2023: Inventory jumped 293.12% in 2022, then plunged 78.71% in 2023.
• A 5-year view of Inventory shows it stood at $949.0 million in 2022, then plunged by 78.71% to $202.0 million in 2023, then sank by 42.08% to $117.0 million in 2024, then surged by 30.77% to $153.0 million in 2025, then retreated by 4.58% to $146.0 million in 2026.
• Business Quant data shows MRNA's Inventory at $146.0 million in Q1 2026, $153.0 million in Q4 2025, and $332.0 million in Q3 2025.